Report Information More information from: https ://www.wis eguyreports .com/reports /495883
LEO Pharma A/S - Product Pipeline Review - 2016 Report / Search Code: WGR495883
Price
1-user P DF : $ 1500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 3000.0
Enterprise P DF : $ 4500.0
LEO Pharma A/S - Product Pipeline Review - 2016 Summary Global Markets Direct’s , ‘LEO Pharma A/S - Product Pipeline Review - 2016’, provides an overview of the LEO Pharma A/S’s pharmaceutical res earch and development focus . The report provides comprehens ive information on the therapeutics under development by LEO Pharma A/S, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and the dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the pipeline therapeutic lands cape of LEO Pharma A/S - The report provides overview of LEO Pharma A/S including its bus ines s des cription, key facts , and locations and s ubs idiaries - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report as s es s es LEO Pharma A/S’s pipeline therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report features LEO Pharma A/S’s out-licens ed and partnered product portfolio and s ummarizes its dormant and dis continued projects Reas ons to buy - Evaluate LEO Pharma A/S’s s trategic pos ition with total acces s to detailed information on its product pipeline - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for LEO Pharma A/S - Identify potential new clients or partners in the target demographic - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding LEO Pharma A/S’s pipeline depth and focus of pipeline therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope
Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 LEO Pharma A/S Snaps hot 6 LEO Pharma A/S Overview 6 Key Information 6 Key Facts 6 LEO Pharma A/S - Res earch and Development Overview 7 Key Therapeutic Areas 7 LEO Pharma A/S - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products /Combination Treatment Modalities 14 LEO Pharma A/S - Pipeline Products Glance 15 LEO Pharma A/S - Late Stage Pipeline Products 15 Pre-Regis tration Products /Combination Treatment Modalities 15 Phas e III Products /Combination Treatment Modalities 16 LEO Pharma A/S - Clinical Stage Pipeline Products 17 Phas e II Products /Combination Treatment Modalities 17 Phas e I Products /Combination Treatment Modalities 18 LEO Pharma A/S - Early Stage Pipeline Products 19 Preclinical Products /Combination Treatment Modalities 19 Dis covery Products /Combination Treatment Modalities 20 LEO Pharma A/S - Drug ProďŹ les 21 (betamethas one dipropionate + calcipotriene) 21 Product Des cription 21 Mechanis m of Action 21 R& D Progres s 21 LEO-43204 22 Product Des cription 22 Mechanis m of Action 22 R& D Progres s 22 aprepitant 23 Product Des cription 23 Mechanis m of Action 23 R& D Progres s 23 ingenol mebutate 24 Product Des cription 24 Mechanis m of Action 24 R& D Progres s 24 LEO-124249 26 Product Des cription 26 Mechanis m of Action 26 R& D Progres s 26 LP-0113 27 Product Des cription 27 Mechanis m of Action 27 R& D Progres s 27 LEO-130852A 28 Product Des cription 28 Mechanis m of Action 28 R& D Progres s 28 LEO-32731 29 Product Des cription 29 Mechanis m of Action 29 R& D Progres s 29 LEO-39652 30 Product Des cription 30 Mechanis m of Action 30 R& D Progres s 30 VBY-891 31 Product Des cription 31 Mechanis m of Action 31 R& D Progres s 31 LP-0067 32 Product Des cription 32 Mechanis m of Action 32 R& D Progres s 32 Small Molecules to Antagonize MCHR1 for Weight Los s 33 Product Des cription 33 Mechanis m of Action 33 R& D Progres s 33 Small Molecules to Activate Protein Kinas e C for Dermatology and Oncology 34
Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 LEO Pharma A/S - Pipeline Analys is 35 LEO Pharma A/S - Pipeline Products by Target 35 LEO Pharma A/S - Pipeline Products by Route of Adminis tration 37 LEO Pharma A/S - Pipeline Products by Molecule Type 38 LEO Pharma A/S - Pipeline Products by Mechanis m of Action 39 LEO Pharma A/S - Recent Pipeline Updates 40 LEO Pharma A/S - Dormant Projects 43 LEO Pharma A/S - Dis continued Pipeline Products 44 Dis continued Pipeline Product Profiles 44 (calcipotriene + hydrocortis one butyrate) 44 TD-1414 44 LEO Pharma A/S - Company Statement 45 LEO Pharma A/S - Locations And Subs idiaries 46 Head Office 46 Other Locations & Subs idiaries 46 Appendix 48 Methodology 48 Coverage 48 Secondary Res earch 48 Primary Res earch 48 Expert Panel Validation 48 Contact Us 48 Dis claimer 49 Lis t of Tables LEO Pharma A/S, Key Information 6 LEO Pharma A/S, Key Facts 6 LEO Pharma A/S - Pipeline by Indication, 2016 9 LEO Pharma A/S - Pipeline by Stage of Development, 2016 10 LEO Pharma A/S - Monotherapy Products in Pipeline, 2016 11 LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2016 12 LEO Pharma A/S - Partnered Products in Pipeline, 2016 13 LEO Pharma A/S - Partnered Products / Combination Treatment Modalities , 2016 14 LEO Pharma A/S - Pre-Regis tration, 2016 15 LEO Pharma A/S - Phas e III, 2016 16 LEO Pharma A/S - Phas e II, 2016 17 LEO Pharma A/S - Phas e I, 2016 18 LEO Pharma A/S - Preclinical, 2016 19 LEO Pharma A/S - Dis covery, 2016 20 LEO Pharma A/S - Pipeline by Target, 2016 36 LEO Pharma A/S - Pipeline by Route of Adminis tration, 2016 37 LEO Pharma A/S - Pipeline by Molecule Type, 2016 38 LEO Pharma A/S - Pipeline Products by Mechanis m of Action, 2016 39 LEO Pharma A/S - Recent Pipeline Updates , 2016 40 LEO Pharma A/S - Dormant Developmental Projects ,2016 43 LEO Pharma A/S - Dis continued Pipeline Products , 2016 44 LEO Pharma A/S, Subs idiaries 46 Lis t of Figures LEO Pharma A/S - Pipeline by Top 10 Indication, 2016 8 LEO Pharma A/S - Pipeline by Stage of Development, 2016 10 LEO Pharma A/S - Monotherapy Products in Pipeline, 2016 11 LEO Pharma A/S - Partnered Products in Pipeline, 2016 13 LEO Pharma A/S - Pipeline by Top 10 Target, 2016 35 LEO Pharma A/S - Pipeline by Route of Adminis tration, 2016 37 LEO Pharma A/S - Pipeline by Molecule Type, 2016 38 LEO Pharma A/S - Pipeline Products by Top 10 Mechanis m of Action, 2016 39
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349